# US 2024/0003885 A1 · Fluorescence resonance energy transfer (fret) nanoprobe and preparation method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003885 A1
- Document ID: US20240003885A1
- Status: Published application
- Kind: A1
- Application number: 17/905,226
- Filed: 2022-05-25
- Published: 2024-01-04
- Earliest claimed: 2022-03-18
- Assignees: Qilu University of Technology
- Applicants: Qilu University of Technology
- Inventors: Yingshu Guo; Xiaofei Zheng
- Web page: https://patentgrep.com/patent/US20240003885A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- B82Y 15/00: Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
- G01N 33/533: with fluorescent label
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present disclosure provides a fluorescence resonance energy transfer (FRET) nanoprobe and a preparation method and use thereof, and belongs to the technical field of targeted nanomaterials. The FRET nanoprobe includes a loading component and an encapsulating component that encapsulates the loading component, where the loading component includes a carrier and DOX coated in the carrier, and the carrier is a carboxyl-modified hollow mesoporous silica nanoparticle (HMSN); and the encapsulating component includes an RVRR peptide and PAMAM/TPE. In the present disclosure, based on condensation properties of a carboxyl group of the carboxyl-modified HMSN, the RVRR peptide and the small-molecule polymer PAMAM/TPE are encapsulated on an outer surface of the HMSN by a reaction of the RVRR peptide that is specifically responsive to Furin and an amino group modified on a surface of the PAMAM/TPE with the carboxyl group on the surface of the HMSN. Therefore, the DOX is effectively encapsulated.

## Claims

### Claim 1

A fluorescence resonance energy transfer (FRET) nanoprobe, comprising a loading component and an encapsulating component that encapsulates the loading component, wherein the loading component comprises a carrier and DOX coated in the carrier, and the carrier is a carboxyl-modified hollow mesoporous silica nanoparticle (HMSN); and the encapsulating component comprises an RVRR peptide and PAMAM/TPE.

### Claim 2 (depends on 1)

The FRET nanoprobe according to claim 1, wherein the carboxyl-modified HMSN and the DOX have a mass ratio of (1-2):(1-2).

### Claim 3 (depends on 1)

A method for preparing the FRET nanoprobe according to claim 1, comprising the following steps:
1) mixing a carboxyl-modified HMSN solution and a DOX solution to obtain an HMSN/DOX solution; and
2) mixing the HMSN/DOX solution, the RVRR peptide, and the PAMAM/TPE to obtain the FRET nanoprobe.

### Claim 4 (depends on 3)

The method according to claim 3, wherein in step 1) and step 2), the mixing is conducted independently at 20° C. to 30° C. for 20 h to 24 h in the dark.

### Claim 5 (depends on 1)

A method for detecting Furin, comprising using the FRET nanoprobe according to claim 1.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the Furin comprises intracellular Furin.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the detection comprises quantitative detection.

### Claim 8 (depends on 1)

A method for preparing an anti-tumor drug, comprising using the FRET nanoprobe according to claim 1.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the anti-tumor drug comprises a targeted anti-tumor drug.

### Claim 10

(canceled)

### Claim 11 (depends on 3)

The method according to claim 3, wherein the carboxyl-modified HMSN and the DOX have a mass ratio of (1-2):(1-2).

### Claim 12 (depends on 5)

The method according to claim 5, wherein the carboxyl-modified HMSN and the DOX have a mass ratio of (1-2):(1-2).

### Claim 13 (depends on 7)

The method according to claim 7, wherein the Furin comprises intracellular Furin.

### Claim 14 (depends on 8)

The method according to claim 8, wherein the carboxyl-modified HMSN and the DOX have a mass ratio of (1-2):(1-2).
